We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00186355
First Posted: September 16, 2005
Last Update Posted: May 14, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Stanford University
September 13, 2005
September 16, 2005
May 14, 2012
October 2003
March 2007   (Final data collection date for primary outcome measure)
PCR positivity in peripheral blood cell collections after cyclophosphamide
Same as current
Complete list of historical versions of study NCT00186355 on ClinicalTrials.gov Archive Site
Enrichment of hematopoietic stem cells
  • - Enrichment of hematopoietic stem cells
  • - Engraftment
Not Provided
Not Provided
 
Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma
Enrichment and Purging of Stem Cells in the Treatment of Non-Hodgkin's Lymphoma
To evaluate the role of purging the hematopoietic cell graft on outcomes for non-Hodgkin's Lymphoma.
To study the use of peripheral blood stem cells which have been treated in an effort to remove tumor cells. The researchers hope to learn whether or not this will be more effective in removing the tumor cells as compared to other methods of purging (the removal of cancer cells).
Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Lymphoma, Non-Hodgkin
Procedure: high dose chemo then auto hematopoietic cell transplant
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
97
February 2010
March 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:- relapsed NHL

Exclusion Criteria:- liver dysfunction

Sexes Eligible for Study: All
up to 75 Years   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00186355
BMT4IJ
77063 ( Other Identifier: Stanford University Alternate IRB Approval Number )
12170 ( Other Identifier: Stanford IRB )
Not Provided
Not Provided
Not Provided
Stanford University
Stanford University
National Institutes of Health (NIH)
Principal Investigator: Robert S Negrin Stanford University
Stanford University
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP